Tudor Investment Corp ET AL Purchases 15,164 Shares of Palomar Holdings, Inc. $PLMR

Key Points

• Tudor Investment Corp increased its Palomar stake by 168% in Q3, buying 15,164 shares and now owning 24,188 shares worth about $2.82 million (≈0.09% of the company).
• Palomar beat quarterly expectations with $2.24 EPS vs. $2.06 estimated and revenue of $253.36M (+62.7% YoY); analysts remain mostly positive with an average target of $165, though some firms have trimmed near‑term estimates.
• Institutional ownership is high (~90%) with major funds (Vanguard, Westfield) adding to positions, while insiders have sold ~63,808 shares (~$7.8M) in the past three months as the stock trades around $127.80 (market cap $3.41B).

Tudor Investment Corp ET AL raised its position in shares of Palomar Holdings, Inc. (NASDAQ:PLMR - Free Report) by 168.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,188 shares of the company's stock after acquiring an additional 15,164 shares during the period. Tudor Investment Corp ET AL owned approximately 0.09% of Palomar worth $2,824,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Palomar by 3.0% in the third quarter. Vanguard Group Inc. now owns 2,631,240 shares of the company's stock worth $307,197,000 after purchasing an additional 77,515 shares during the period. Westfield Capital Management Co. LP boosted its stake in Palomar by 81.0% during the 3rd quarter. Westfield Capital Management Co. LP now owns 738,528 shares of the company's stock valued at $86,223,000 after purchasing an additional 330,592 shares during the period. Dimensional Fund Advisors LP grew its holdings in Palomar by 1.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 596,050 shares of the company's stock valued at $69,584,000 after buying an additional 9,731 shares during the last quarter. Stephens Investment Management Group LLC grew its holdings in Palomar by 3.6% in the 3rd quarter. Stephens Investment Management Group LLC now owns 579,458 shares of the company's stock valued at $67,652,000 after buying an additional 19,908 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in Palomar by 290.2% in the 2nd quarter. Alliancebernstein L.P. now owns 497,080 shares of the company's stock worth $76,675,000 after buying an additional 369,697 shares during the period. 90.25% of the stock is owned by institutional investors and hedge funds.

Palomar Trading Down 4.4%

Shares of PLMR stock opened at $127.80 on Friday. Palomar Holdings, Inc. has a 12 month low of $107.75 and a 12 month high of $175.85. The company has a market capitalization of $3.41 billion, a P/E ratio of 17.80 and a beta of 0.54. The stock has a 50 day moving average of $123.53 and a two-hundred day moving average of $123.40.

Palomar (NASDAQ:PLMR - Get Free Report) last issued its earnings results on Wednesday, February 11th. The company reported $2.24 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.18. The business had revenue of $253.36 million during the quarter, compared to analyst estimates of $204.58 million. Palomar had a return on equity of 22.77% and a net margin of 22.50%.Palomar's revenue was up 62.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.52 earnings per share. Sell-side analysts predict that Palomar Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Key Headlines Impacting Palomar

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Zacks Research raised its FY‑2027 EPS view to $10.26 (from $9.66) and nudged several quarterly estimates higher, implying a stronger near‑term earnings trajectory that could support multiple expansion.
• Positive Sentiment: Zacks also bumped Q2‑2027 to $2.41 and Q4‑2027 to $2.12, which may raise the bar for consensus and help near‑term beats.
• Positive Sentiment: Sell‑side support remains from some large firms — Keefe, Bruyette & Woods and JPMorgan raised target prices and maintained bullish stances, and Evercore initiated coverage with an outperform view, providing upside to sentiment and price targets. Palomar NASDAQ: PLMR Stock Price Expected to Rise, Keefe, Bruyette & Woods Analyst Says
• Positive Sentiment: Positive coverage pieces (Zacks/MSN) highlight Palomar as a long‑term growth story tied to its medical stop‑loss franchise and program management expansion, which supports buy‑and‑hold investors. Why Palomar (PLMR) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Insider activity: President Jon Christianson sold 3,000 shares (~$375k) under a pre‑arranged Rule 10b5‑1 plan — a material sale but disclosed and planned, so market reaction may be limited. Palomar NASDAQ: PLMR President Sells $375,000.00 in Stock
• Neutral Sentiment: High institutional ownership (~90%) and recent small rebalances by funds suggest the stock is largely held by institutions, which can dampen volatility but also slow retail‑led rallies.
• Negative Sentiment: Zacks trimmed Q1‑2028 EPS to $2.94 (from $3.17) and cut FY‑2028 to $11.46 (from $11.83); downward revisions to forward estimates are a near‑term negative for upside expectations.
• Negative Sentiment: Some independent raters (Wall Street Zen, Weiss) moved the stock from Buy to Hold — mixed-to‑softer sentiment that could limit fresh buyer interest until clearer beats/guidance emerge.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Weiss Ratings lowered Palomar from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday. JPMorgan Chase & Co. boosted their target price on shares of Palomar from $155.00 to $160.00 and gave the stock an "overweight" rating in a research report on Monday, February 23rd. Evercore started coverage on shares of Palomar in a report on Monday, February 9th. They issued an "outperform" rating and a $150.00 price target for the company. Wall Street Zen lowered shares of Palomar from a "buy" rating to a "hold" rating in a research report on Sunday, March 1st. Finally, Keefe, Bruyette & Woods boosted their price objective on shares of Palomar from $183.00 to $186.00 and gave the stock an "outperform" rating in a report on Tuesday. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $165.00.

Insider Transactions at Palomar

In other news, CEO Mac Armstrong sold 3,500 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $120.58, for a total value of $422,030.00. Following the completion of the transaction, the chief executive officer owned 339,888 shares in the company, valued at approximately $40,983,695.04. This represents a 1.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Knutzen sold 281 shares of Palomar stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $128.04, for a total transaction of $35,979.24. Following the sale, the insider owned 27,579 shares in the company, valued at approximately $3,531,215.16. This trade represents a 1.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 63,808 shares of company stock worth $7,814,365. 3.70% of the stock is currently owned by company insiders.

About Palomar

Palomar Holdings, Inc NASDAQ: PLMR is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.